Financière de Tubize SA Bennfentes tulajdonlás
Mi az Financière de Tubize SA Bennfentes tulajdonlás?
A Bennfentes tulajdonlás az Financière de Tubize SA - 56.85%
Mi a Bennfentes tulajdonlás meghatározása?
A bennfentes tulajdonjog kiszámítása a bennfentesek tulajdonában lévő részvények (részvényesek, akik a vállalat több mint 5% -át, vagy a vállalat tisztségviselőjét vagy igazgatóját birtokolják) teljes létszámával, osztva a teljes részvénykivonással.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Bennfentes tulajdonlás a Health Care szektor a EURONEXT-on cégekben a Financière de Tubize SA -hoz képest
Mit csinál Financière de Tubize SA?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
bennfentes tulajdonlás -hoz hasonló cégek Financière de Tubize SA
- Las Vegas Sands nak Bennfentes tulajdonlás 56.80% van
- Kakatiya Cement Sugar and Industries nak Bennfentes tulajdonlás 56.81% van
- McChip Resources nak Bennfentes tulajdonlás 56.82% van
- Laurus Labs nak Bennfentes tulajdonlás 56.83% van
- Reitmans (Canada) nak Bennfentes tulajdonlás 56.84% van
- Tecnoglass Inc nak Bennfentes tulajdonlás 56.85% van
- Financière de Tubize SA nak Bennfentes tulajdonlás 56.85% van
- Fairfax Africa nak Bennfentes tulajdonlás 56.86% van
- Conart Engineers nak Bennfentes tulajdonlás 56.86% van
- Moelis Australia nak Bennfentes tulajdonlás 56.86% van
- Western Pacific Trust nak Bennfentes tulajdonlás 56.87% van
- Crexendo nak Bennfentes tulajdonlás 56.88% van
- Helios Fairfax Partners nak Bennfentes tulajdonlás 56.88% van